Axillary Node Management for Breast Cancer: Is Less More?
Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.
Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.
This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.
The CTS5 model is based on nodal status, tumor size, 3 categories of tumor grade, and age as a continuous variable.
At a previously reported median follow-up of 5 years, no DFS difference was detected between patients in the 2 study groups. This analysis was performed after a median follow-up of 9.8 years.
Study findings indicate that margin widths of at least 2 mm are associated with reduced risk of ipsilateral breast failure compared with narrower but uninvolved margins.
Translating these findings into clinical practice will require careful conversations with patients to weigh toxicity and potential benefits for each individual.
Further follow-up should help to clarify the safety and benefits of OFS for late breast cancer OS.
Elevated COX2 levels are associated with breast cancer progression. COX2 is transcriptionally regulated and enhances the aromatase pathway, especially in estrogen receptor-positive tumors.
Patients with stage II to III HER2+ breast cancer underwent tumor biopsy and were then randomly assigned to receive paclitaxel plus trastuzumab alone or with lapatinib for 16 weeks before surgery.
The findings support the use of pCR as a primary endpoint for accelerated approval of new drugs when EFS is evaluated in the relevant patient population.